Follow-up vs. chemo after surgery for early stomach cancer
This trial compares two approaches after surgery for early-stage stomach or GEJ cancer: close monitoring (follow-up) vs. adjuvant chemotherapy (chemo given after surgery). It aims to see if follow-up alone is as good as chemo for patients with this stage, potentially avoiding chemo side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with stomach or gastroesophageal junction (GEJ) adenocarcinoma that is stage IB or IIA (not T2N1).
- You have had surgery to remove the tumor, and it was considered curative.
- Your overall health is good enough for treatment (ECOG score 0–2).
- Your blood tests and organ functions meet the study's requirements (kidney, liver, blood counts, etc.).
- You have not had other cancer treatments (except the surgery) and have no other recent cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy (DOS) plus an immunotherapy drug (Adebrelimab) given before surgery for people with locally advanced stomach or gastroesophageal junction cancer. The goal is to see if the treatment shrinks the tumor and improves outcomes.
This trial is for people who have already had chemotherapy and surgery for stomach cancer. It compares different follow-up approaches to see if skipping more chemo after surgery is safe and effective.
This study tests whether giving personalized follow-up treatment after stomach cancer surgery and chemotherapy can help prevent the cancer from coming back. The treatment plan is tailored based on how well the tumor responded to initial chemotherapy.
This trial tests a combination of immunotherapy drugs (sintilimab, chemotherapy, and sometimes ipilimumab) given before surgery to shrink stomach or esophageal junction tumors, then continued after surgery. The goal is to improve survival in patients with resectable (removable) gastric or gastroesophageal junction cancer.
This Phase 1 trial tests how well a tailored (response-adapted) chemotherapy plan works before surgery for stomach or gastroesophageal junction cancer. It aims to improve treatment planning while checking early safety.
This trial tests a combination of chemotherapy drugs (nab-paclitaxel, oxaliplatin, and S-1) plus an immunotherapy drug (sintilimab) given before surgery for younger people (ages 16 to 45) with stomach or gastroesophageal junction cancer that can be removed. The goal is to see if this approach shrinks tumors and improves outcomes.
Hear when a new Stage IB-IIA Adenocarcinoma of the Stomach or Gastroesophageal Junction trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.